Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00035308 | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease | PHASE3 | COMPLETED | 330 | — | — | - | Dec 1, 2002 | Sep 25, 2006 | 82 | United States, Austria +8 |
| Name | Type | Description |
|---|---|---|
| Abetimus sodium (LJP 394) | DRUG | - |
Inclusion Criteria * Diagnosed with SLE * Historical evidence of SLE renal disease * Elevated levels of dsDNA antibodies * Weight of 40 kg or greater Exclusion Criteria * Active SLE renal disease * Use of certain anti-inflammatory or cytotoxic therapies or therapeutic interventions during the mon...